期刊文献+

心房纤颤患者血清sCD40L及hs-CRP的动态变化

Dynamic changes of soluble sCD40 Ligand and hyper-sensitivity C-reactive protein in Patients with atrial fibrillation
下载PDF
导出
摘要 目的动态观察心房纤颤(AF)患者血清可溶性CD40配体(sCD40L)及超敏C-反应蛋白(hs-CRP)的变化,探讨其临床意义。方法选取43例AF患者及20例对照,用ELISA法检测血清sCD40L水平,采用免疫透射比浊法检测血清hs-CRP水平;AF患者接受射频消融术,动态观察术前及术后0、12、24 h研究指标的变化。结果①与射频消融术前相比,sCD40L、hs-CRP在术后0、12、24 h均明显降低(P<0.05);射频消融术后0、12、24 h 3组间相互比较,sCD40L及hs-CRP随术后时间的延长而呈下降趋势,但水平差异无统计学意义(P>0.05);②对照组sCD40L及hs-CRP水平低于AF组,2组差异有统计学意义(P<0.05)。结论检测sCD40L及hs-CRP对临床AF治疗具有一定的指导意义,炎症机制可能在AF的发生发展过程中发挥作用。 Objective To observe the dynamic changes of soluble CD40 ligand(sCD40L)concentration and hyper-sensitivity C-reactive protein(hs-CRP)in patients with atrial fibrillation(AF),to explore the clinical significance.Methods 43 patients with AF and 20 controls included in the research,ELISA and immunoturbidimetric assay was used to test the serum concentration of sCD40L and hs-CRP,respectively.The circulating concentrations of sCD40L and hs-CRP were prospectively measured(both pre-procedure,and 0h,12h and 24h after the procedure)in 43 AF undergoing catheter radiofrequency ablation.Results The serum concentration of sCD40L and hs-CRP were significantly higher pre-procedure in study patients(P0.05).The two inflammatory markers gradually decreased among the three groups after CRA,while there was no statistical significance(P0.05).The serum concentration of sCD40L and hs-CRP in controls was lower than that in AF(P0.05).Conclusion It is useful to test sCD40L and hs-CRP for treatment in patients with AF,inflammatory mechanisms may play an important role in the development of AF.
出处 《宁夏医学杂志》 CAS 2012年第4期298-300,共3页 Ningxia Medical Journal
基金 宁夏医科大学校级资助项目(XM 201043)
关键词 房颤 可溶性CD40配体 超敏C反应蛋白 射频消融术 Atrial fibrillation sCD40L hs-CRP Catheter radiofrequency ablation
  • 相关文献

参考文献7

  • 1贺永明,杨向军.筛选心房颤动危险因素的病例对照研究[J].中国循环杂志,2005,20(2):114-117. 被引量:4
  • 2Chung MK,Martin DO,Sprecher D,et al.C-reactive protein ele-vation in patients with atrial arrhythmias:inflammatory mechanismsand persistence of atrial fibrillation[J].Circulation,2001,104:2886-2891.
  • 3Charalambos A,Tim V,Cheerag S,et al.Preoperative sCD40L lev-els predict risk of atrial fibrillation after off-pump coronary artery bypass graft surgery[J].Circulation,2009,120:170-176.
  • 4Hamza D,Vatan B,Huseyin K,et al.Prognostic value of plasma sol-uble CD40 ligand in patients with chronic non-valvular atrial fi-brillation[J].Europace,2008,10:210-214.
  • 5Anirban C,Irene C,Nimai P,et al.Soluble CD40 ligand,platelet surface CD40ligand,and total platelet CD40ligand in atrial fibrilla-tion:relationship to soluble P-selectin,stroke risk factors,and risk factor intervention[J].Lip Chest,2008,134:574-581.
  • 6Yan JC,Zhu J,Gao L,et al.The effect of elevated serum soluble CD40ligand on the prognostic value in patients with acute coronary syndromes[J].Clin Chim Acta,2004,343:155-159.
  • 7孙小军,卢竞前,李易.不同冠心病炎症因子测定及意义[J].中国实用医药,2010,5(3):75-76. 被引量:2

二级参考文献18

  • 1Schonbeck U, Libby P. CD40 signaling and plaque instability. Circulation research, 2001,89 (12) : 1092-1103.
  • 2Conti CR. Updated pathophysiologic concepts in unstable coronary artery disease. Am Heart J, 2001,141(2 suppls) :S12-S14.
  • 3Davies MJ. The pathophysiology of acute coronary syndromes. Heart,2000, 83(3) :361-366.
  • 4Oltrona L, Ardission D, Merlini PA, et al. C-reactive elevation and early outcome in patients with unstable angina pectoris. Am J Cardiol,1997,80(8) : 1002-1006.
  • 5Blake GJ,Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coil Cardiol,2003 ,41 (4SupplS) : S37-S47.
  • 6Ridker PM, Bassuk SS,Toth PP. C-reactive protein and risk of cardiovascular disease : Evidence and clinicial application. Curr Atheroscler Rep, 2003, 5(5) :341 -349.
  • 7Bruemmer D, Riggers U, Holzmeister J, et al. Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atheroscleretic lesions. Am J Cardiol, 2001,87( 1 ) :21-27.
  • 8Franceseo C, Claudio F, Giovambattista D. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation,2003, 108 ( 22 ) : 2776-2782.
  • 9Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological intervention in atrial fibrillation(PIAF): a cet, 2000, 356:1789-1794.
  • 10Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and randomized trial. Lanrhythm control in patients with atrial fibrillation. N Engl J Med, 2002, 347: 1825-1833.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部